inst some of 
the 
worlds 
largest 
corporations. These 
corporations have highly developed sales and 
marketing networks and more importantly, extensive 
financial 
resources 
beyond 
comparison with those of IBA. Furthermore, there is always the possibility that new 
technology notably a revolutionary therapy in 
the treatment of cancer that would render a part 
of IBAs current product line obsolete could be 
developed. The development and marketing of technology 
resulting in novel therapies do nevertheless 
require a relatively long period of time.